# VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine

> **NCT04130282** · PHASE1 · TERMINATED · sponsor: **University of Oxford** · enrollment: 1 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** Pfs25-IMX313/Matrix-M1

## Key facts

- **NCT ID:** NCT04130282
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-27
- **Primary completion:** 2020-09-22
- **Final completion:** 2020-09-22
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Delays caused by Covid-19
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04130282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04130282, "VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04130282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*